Increasing Investment by Top Market Players and Governments to Drive Global Influenza Vaccines Market

According to our new research study on "Influenza Vaccines Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Vaccine Type, Virus Type, Technology, and Route of Administration," the market was valued at US$ 7,478.53 million in 2021 and is projected to reach US$ 12,272.49 million by 2028. It is estimated to grow at a CAGR of 7.4% from 2022 to 2028. Increasing government support to promote influenza vaccination and investment by top market players and governments worldwide are driving the market. However, the high cost of vaccine development is hampering the market's growth.

Influenza virus causes flu which is a contagious respiratory illness that infects nose, throat and lungs. It can mild or severe and sometimes may lead to death. Flu vaccination every year can help in preventing flu. However, this can be deadly, especially in high-risk groups. Aged population, pregnant women and people with one or more chronic disease or with weak immune systems are at high risk. Influenza vaccines/flu shots protect against the four influenza viruses subtypes that are most common. Most of the influenza vaccines are "flu shots" given with a needle, usually in the arm, but nasal spray flu vaccine are also available.

Market players and governments worldwide are increasing their investments in vaccine development and immunization. For instance, In March 2021, Sanofi announced an approximately US$ 925 million investment in a new vaccine manufacturing plant at its pre-existing site in Toronto and Canada. Investments in the new facility will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccines, increasing availability in Canada, the US, and Europe in the years to come.

In April 2021, 3 levels of the government?federal, provincial, and municipal?supported Sanofi Pasteur in building an "end-to-end" influenza vaccines factory in Toronto. The partners are expected to invest nearly US$ 1 billion to get the site up and running, slated for 2027. Paris-based Sanofi, for its part, will invest more than US$ 55 million, create 165 new eligible jobs, and maintain another 1,100. The federal government is investing US$ 55 million, while the Ontario government is contributing US$ 55 million, making it a US$ 925 million project. In addition, Sanofi will also invest at least US$ 79 million annually over 8 years to fund research and development in Canada.

In June 2021, The European Investment Bank signed a US$ 30.55 million global vaccine distribution agreement with Univercells, a biotech company, to mass produce the COVID-19 vaccine at a new Belgian site. It helped build other vaccine factories around the world. In April 2022, the Bank provided a US$ 15.27 million loan to Italian biomedical research company IRBM to expand its vaccine production capacity and strengthen research on coronaviruses and other diseases.

Thus, the increase in investment by top market players and governments worldwide is bolstering the influenza vaccines market.

Moderna, Inc.; SEQIRUS; Sanofi; GlaxoSmithKline plc.; Hualan Biological Engineering Inc.; Emergent BioSolutions Inc.; Mitsubishi Chemical Group Corporation; Serum Institute of India Pvt. Ltd; MYLAN NV; and AstraZeneca are the leading companies operating in the influenza vaccines market.

Based on vaccine type, the influenza vaccines market is segmented into quadrivalent vaccines and trivalent vaccines. Based on virus type, the market is segmented into influenza virus type A and influenza virus type B. Based on technology, the market is segmented into egg-based and cell-based. Based on route of administration, the market is segmented into injection and nasal spray. By geography, the global market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com